# Medicinal Fungi Research (Lion's Mane and Others) Date: 2026-04-29 Scope: practical evidence review for commonly used "functional/medicinal" mushrooms, with emphasis on human evidence quality, safety, and interaction risk. ## Executive Takeaways - The strongest human evidence is **adjunct oncology use** for turkey tail (PSK/PSP extracts) in specific Asian clinical settings; this does **not** equal universal anticancer efficacy across all products. - For Lion's Mane, early human data suggest possible cognitive/mood/stress benefits in some groups, but findings are mixed and often based on small studies. - Reishi has mixed efficacy data and a low but important signal for **rare liver injury**, especially with some powdered products/case reports. - Cordyceps has limited human evidence for stamina and kidney-related outcomes, and meaningful interaction concerns (bleeding and glucose lowering). - Maitake has promising immunometabolic signals but limited high-quality clinical trials; interaction concerns include warfarin and glucose-lowering therapies. - Chaga has very limited human efficacy data and a notable safety concern: **oxalate nephropathy** in case reports with high/long use. - Major practical issue across all fungi: product quality variability (species, extraction, dose, contamination, mycelium vs fruiting body, standardization). ## Evidence Grading Used Here - **Moderate**: multiple human studies with some consistency, but still not definitive for broad clinical use. - **Low-Moderate**: small studies/pilot RCTs or heterogenous outcomes. - **Low**: mostly preclinical data or case reports, limited controlled human evidence. ## 1) Lion's Mane (*Hericium erinaceus*) ### What it is usually used for - Cognitive support, memory, mood, stress. ### Human evidence snapshot - Small human RCTs/pilot studies suggest possible improvements in selected cognitive or stress outcomes, but results are inconsistent across endpoints and populations. - One 2023 pilot RCT in healthy young adults found faster Stroop performance acutely and trend-level stress reduction after 28 days, with mixed/null findings on other measures. - Prior studies in mild cognitive impairment/older adults show signals of benefit, but sample sizes are small and formulations differ. ### Safety and interactions - Generally well tolerated in short-term trials; reported adverse effects include abdominal discomfort, nausea, diarrhea, rash. - LiverTox (NIH) indicates Lion's Mane is an **unlikely** cause of clinically apparent liver injury (Likelihood score E). - Long-term safety and product-standardization issues remain. ### Practical verdict - **Evidence level: Low-Moderate** for cognition/mood support. - Reasonable for cautious trial use, but avoid overclaiming and monitor tolerance. ## 2) Reishi / Lingzhi (*Ganoderma lucidum/lingzhi*) ### What it is usually used for - Immune support, vitality/stamina, metabolic and LUTS claims, adjunct oncology contexts. ### Human evidence snapshot - Clinical findings are mixed; some small studies suggest immune modulation or symptom benefits, while RCTs for cardiovascular/metabolic risk factors have often been negative or modest. - Oncology-oriented literature suggests potential adjunctive roles in selected settings, but not as standalone treatment. ### Safety and interactions - LiverTox reports rare but plausible clinically apparent liver injury (Likelihood score D: possible rare cause), including severe case reports. - MSK also flags bleeding risk with anticoagulants/antiplatelets and cautions regarding immunosuppressants. - Possible CYP interaction signals (preclinical) and lab interference signal (CA72-4 with some spore products). ### Practical verdict - **Evidence level: Low-Moderate** overall; stronger for immune-biomarker modulation than hard outcomes. - Use conservative dosing and avoid in liver-risk contexts unless supervised. ## 3) Turkey Tail (*Trametes/Coriolus versicolor*; PSK/PSP) ### What it is usually used for - Immune support; adjunct use in cancer care (especially PSK in Japan). ### Human evidence snapshot - NCI PDQ and MSK summaries indicate the best-established human track record among medicinal mushrooms for adjunct oncology use in specific cancers/settings. - Historical Japanese data suggest improved outcomes in some adjuvant contexts (e.g., gastric/colorectal cohorts), but applicability depends on product type and treatment setting. ### Safety and interactions - Generally well tolerated; reported minor effects include dark stool/fingernail darkening and low-grade GI/hematologic effects in some settings. - Important to distinguish standardized extracts (PSK/PSP) from non-standard over-the-counter products. ### Practical verdict - **Evidence level: Moderate** (within defined adjunct-oncology contexts, especially historical PSK data). - For general wellness claims outside these contexts, certainty drops. ## 4) Cordyceps (*Ophiocordyceps sinensis* and related products) ### What it is usually used for - Energy/stamina, immune support, kidney support. ### Human evidence snapshot - Mixed exercise-performance data. - Some studies suggest renal-function related benefits in specific populations, but systematic analyses cite insufficient certainty for broad recommendations. ### Safety and interactions - MSK notes potential additive hypoglycemic effects and antiplatelet/bleeding effects. - Case report of excessive post-procedural bleeding has been documented. - Caution for people on insulin/antidiabetic agents or anticoagulant/antiplatelet therapy. ### Practical verdict - **Evidence level: Low-Moderate**, condition-specific and formulation-dependent. ## 5) Maitake (*Grifola frondosa*) ### What it is usually used for - Immune support, glucose/lipid support, blood pressure/cholesterol claims. ### Human evidence snapshot - Human data are limited and generally small; some studies report immunomodulatory effects in oncology-related contexts. - Stronger claims remain preclinical or early-stage. ### Safety and interactions - MSK flags interaction risk with warfarin (INR elevation case) and additive hypoglycemic effects. - Generally food-safe as culinary mushroom; supplement potency and effects differ. ### Practical verdict - **Evidence level: Low-Moderate** for immunometabolic support; stronger evidence still needed. ## 6) Chaga (*Inonotus obliquus*) ### What it is usually used for - Antioxidant/immune claims, general "wellness" positioning. ### Human evidence snapshot - Human efficacy evidence is weak; much of the literature is preclinical. ### Safety and interactions - Repeated case reports describe **oxalate nephropathy** and severe kidney injury after prolonged/high intake in susceptible individuals. - Interaction concerns are commonly raised for glucose-lowering and anticoagulant contexts, but robust clinical interaction trials are lacking. ### Practical verdict - **Evidence level: Low** for broad benefit claims; safety profile requires caution, especially in kidney-risk users. ## Cross-Cutting Safety Rules (Practical) - Prefer reputable products with third-party testing and clear species/extract labeling. - Start low, increase slowly, and avoid combining many fungi at full doses on day 1. - Stop and reassess if GI symptoms, rash, jaundice, dark urine, unusual bruising/bleeding, or edema appear. - Use extra caution (or avoid unsupervised use) if you have: - anticoagulant/antiplatelet therapy, - diabetes medication, - liver disease history, - kidney disease history, - autoimmune disease or immunosuppressant therapy, - active cancer treatment. ## Research Gaps That Matter - Larger, longer, independently funded RCTs with standardized extracts. - Better pharmacokinetic and interaction studies. - Stronger post-market quality surveillance for product identity/purity. - Clinically meaningful endpoints (not only immune markers) in diverse populations. ## Practical "Confidence" Summary - **Most actionable currently:** Turkey tail extracts (PSK/PSP) in specific adjunct-oncology contexts. - **Promising but early:** Lion's Mane for cognition/stress; Maitake for immunometabolic support. - **Use with heightened caution:** Reishi (rare liver injury signal) and Chaga (oxalate kidney injury reports). - **Conditional use:** Cordyceps where goals and medication profile are compatible. ## Sources (high-priority) - NCI PDQ, Medicinal Mushrooms (Patient Version): https://www.cancer.gov/about-cancer/treatment/cam/patient/mushrooms-pdq - NIH LiverTox, Lion's Mane (2024 update): https://www.ncbi.nlm.nih.gov/books/NBK599740/ - NIH LiverTox, Lingzhi/Reishi (2024 update): https://www.ncbi.nlm.nih.gov/books/NBK609014/ - MSK About Herbs, Lion's Mane: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/lions-mane-mushroom - MSK About Herbs, Reishi Mushroom: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/reishi-mushroom - MSK About Herbs, Cordyceps: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/cordyceps - MSK About Herbs, Maitake: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/maitake - MSK About Herbs, Coriolus/Turkey Tail: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/coriolus-versicolor - PubMed (Lion's Mane 2019 trial): https://pubmed.ncbi.nlm.nih.gov/31413233/ - PubMed (Lion's Mane 2023 pilot RCT): https://pubmed.ncbi.nlm.nih.gov/38004235/ - PubMed (Chaga oxalate nephropathy case report): https://pubmed.ncbi.nlm.nih.gov/35451393/ - PubMed (Chaga oxalate nephropathy earlier case): https://pubmed.ncbi.nlm.nih.gov/23149251/ --- This document is educational and should not replace individualized medical advice.